Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
November 18 2021 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Invetx, a pioneer in
protein-based therapeutics for animal health, today announced an
extension to their existing antibody therapeutic partnership. The
extended agreement covers the addition of next-generation synthetic
antibody phage display technology for the discovery of novel
monoclonal antibodies (mAbs) for the treatment of multiple diseases
in cats and dogs.
“Our initial partnership with Twist to develop canine and feline
TAO (Twist Antibody Optimization) platforms and use them to
optimize development of our veterinary biotherapeutics has been
very successful,” said Juergen Horn, PhD, chief executive officer
of Invetx. “With this expanded agreement, we are adding
complementary in vitro synthetic antibody discovery capabilities to
our existing in vivo platform. This combination enables us to
generate best-in-class therapeutics for an even broader range of
targets to treat chronic and serious conditions in dogs and
cats.”
Under the terms of the agreement, Twist Biopharma, a division of
Twist Bioscience, leverages its “Library of Libraries,” a panel of
synthetic antibody phage display libraries to identify potential
therapeutic antibody candidates against specific feline and canine
disease targets provided by Invetx. Twist has already generated
fully feline and canine synthetic antibody libraries and from them,
has begun to identify drug candidates. Twist will work with Invetx
to validate and optimize any resulting new antibody candidates.
“Our continued and expanded partnership with Invetx illustrates
the power and broad applicability of our antibody discovery
technology,” said Emily M. Leproust, PhD, chief executive officer
and co-founder of Twist Bioscience. “Animal health, especially pet
care, is an important and fast-growing market. As a dog lover and
owner of multiple dogs, I’m personally pleased to see the
development of targeted biologics in animal health and at Twist, we
love supporting Invetx as they aim to extend and improve quality of
life of our pets.”
About Invetx
Invetx is building the world’s premier biotechnology platform
for protein-based therapeutics in animal health to transform
standards of care in veterinary medicine. The company recently
launched its first clinical field study in dogs with IVX-01, a
proprietary, novel, fully canine, high-affinity and half-life
extended monoclonal antibody in September 2021.
Invetx completed a $25.5 million Series A financing in 2020 with
investors Anterra Capital, Casdin Capital and funds managed by
Tekla Capital Management, LLC. Strategic investment partners are
AbCellera, a global technology company with a centralized operating
system for antibody discovery, and WuXi Biologics, a global company
with leading biologics technology platforms. Invetx is a private
company headquartered in Boston, Massachusetts. For more
information, see www.invetx.com.
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we
can construct proprietary antibody libraries precisely designed to
match sequences that occur in the human body. This library of
libraries gives our partners an integral and unbiased resource for
antibody therapeutic discovery and optimization. This precise and
rational approach to library fabrication combined with
sophisticated bioinformatics and software expertise expedites
antibody discovery by decreasing risk, increasing speed, and
lowering the failure rate for antibody therapeutic development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn |
YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to
successfully discover novel therapeutic antibodies against disease
targets in dogs and cats, are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known
and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties of the ability to attract
new customers and retain and grow sales from existing customers;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology could make the products
Twist Bioscience is developing obsolete or non-competitive; the
retention of employees of acquired companies and the ability of
Twist Bioscience to successfully integrate acquired companies and
to achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021, and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether because of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211118005418/en/
Invetx Juergen Horn, PhD Chief Executive Officer
juergen.horn@invetx.com
Susan Kinkead (media) susan@kinkeadcomm.com 415-509-3610
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925-202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2024 to Oct 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Oct 2023 to Oct 2024